{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:35:35Z","timestamp":1789781735899,"version":"4.0.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/jcp.0b013e3182217a69","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T02:49:40Z","timestamp":1308624580000},"page":"489-496","source":"Crossref","is-referenced-by-count":48,"title":["Differential Effectiveness of Antipsychotics in Borderline Personality Disorder"],"prefix":"10.1097","volume":"31","author":[{"given":"Theo J.M.","family":"Ingenhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo J.","family":"Duivenvoorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1176\/appi.ajp.160.2.274","article-title":"The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder.","volume":"160","author":"Zanarini","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R2-13-20210128","first-page":"903","article-title":"Treatment histories of borderline inpatients.","volume":"65","author":"Zanarini","year":"2001","journal-title":"Compr Psychiatry"},{"issue":"suppl 10","key":"R3-13-20210128","first-page":"1","article-title":"Practice guideline for the treatment of patients with borderline personality disorder.","volume":"158","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701685224","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of personality disorders.","volume":"8","author":"Herpertz","year":"2007","journal-title":"World J Biol Psychiatr"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/bjp.196.2.158","article-title":"Pharmacotherapy for borderline personality disorder: NICE guideline.","volume":"196","author":"Kendall","year":"2010","journal-title":"Br J Psychiatry"},{"key":"R10-13-20210128","first-page":"195","article-title":"Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation.","volume":"62","author":"Soloff","year":"1998","journal-title":"Bull Menninger Clin"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0193-953X(05)70150-7","article-title":"Psychopharmacology of borderline personality disorder.","volume":"23","author":"Soloff","year":"2000","journal-title":"Psychiatr Clin North Am"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.08r04526gre","article-title":"Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials.","volume":"71","author":"Ingenhoven","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information.","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0165-0327(82)90026-X","article-title":"Pharmacological prevention of suicidal behaviour.","volume":"4","author":"Montgomery","year":"1982","journal-title":"J Affect Disord"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archpsyc.1986.01800070070009","article-title":"Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo.","volume":"43","author":"Goldberg","year":"1986","journal-title":"Arch Gen Psychiatry"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/archpsyc.1988.01800260015002","article-title":"Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.","volume":"45","author":"Cowdry","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00004714-198908000-00002","article-title":"Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.","volume":"9","author":"Soloff","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archpsyc.1993.01820170055007","article-title":"Efficacy of phenelzine and haloperidol in borderline personality disorder.","volume":"50","author":"Soloff","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1176\/ajp.150.12.1843","article-title":"Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.","volume":"150","author":"Cornelius","year":"1993","journal-title":"Am J Psychiatry"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4088\/JCP.v62n1103","article-title":"Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.","volume":"62","author":"Zanarini","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.v65n0118","article-title":"Olanzapine versus placebo in the treatment of borderline personality disorder.","volume":"65","author":"Bogenschutz","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","article-title":"Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.","volume":"162","author":"Soler","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"suppl 1","key":"R27-13-20210128","first-page":"S191","article-title":"A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo-controlled study (P102). Presented at the XXIVth CINP Congress, Chicago, IL, July 9-13.","volume":"9","author":"Zanarini","year":"2006","journal-title":"Int J Neuropsychopharm"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","article-title":"Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.","volume":"163","author":"Nickel","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"4","key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.v69n0412","article-title":"Ziprazidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.","volume":"69","author":"Pascual","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"suppl 1","key":"R30-13-20210128","first-page":"S191","article-title":"Olanzapine for the treatment of borderline personality disorder: a flexible-dose12-week randomized double-blind placebo-controlled study (P101). Presented at the XXIVth CINP Congress, Chicago, IL, July 9-13.","volume":"9","author":"Schulz","year":"2006","journal-title":"Int J Neuropsychopharm"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","article-title":"Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomized double-blind placebo-controlled study.","volume":"193","author":"Schulz","year":"2008","journal-title":"Br J Psychiatry"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4088\/JCP.v69n0617","article-title":"Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.","volume":"69","author":"Linehan","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"suppl 4","key":"R33-13-20210128","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1016\/S0924-977X(08)70622-9","article-title":"The effect of quetiapine on psychotic-like symptoms and general psychopathology in patients with borderline personality disorder: a randomized placebo-controlled trial.","volume":"18","author":"van den Broek","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.v64n0602","article-title":"Risperidone in the treatment of schizotypal personality disorder.","volume":"64","author":"Koenigsberg","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R38-13-20210128","first-page":"CD005653","article-title":"Pharmacological interventions for people with borderline personality disorder.","volume":"3","author":"Binks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.yic.0000224784.90911.66","article-title":"Efficacy of pharmacotherapy against traits of borderline personality disorder: meta-analysis of randomized controlled trails.","volume":"21","author":"Nose","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1521\/pedi.2009.23.2.156","article-title":"Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms.","volume":"23","author":"Mercer","year":"2009","journal-title":"J Personal Disord"},{"key":"R41-13-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","article-title":"Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials.","volume":"196","author":"Lieb","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"1","key":"R42-13-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/JCP.0b013e3181c826ff","article-title":"Olanzapine versus haloperidol in the management of borderline personality disorder. A randomized double-blind trial.","volume":"30","author":"Shafti","year":"2010","journal-title":"J Clin Psychopharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201108000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:31:55Z","timestamp":1786044715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201108000-00013"}},"subtitle":["Meta-Analyses of Placebo-Controlled, Randomized Clinical Trials on Symptomatic Outcome Domains"],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182217a69","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}